Stable S-adenosylmethionine salts, the process for their preparation, and therapeutic compositions which contain them as active principle

Claim 2

S-adenosylmethionine (SAM) salts of formula ##STR5## in which X is the acid equivalent of a strong mineral acid of pK less than 2.5, and n is 4, 5 or 6.

Claim 3

Salts as claimed in claim 1, of formula ##STR6## in which X is Cl - , 1/2(SO 4 -- ), or H 2 PO 4 - .

Claim 4

Salts as claimed in claim 1, of formula ##STR7## in which X is Cl - , 1/2(SO 4 -- ), or H 2 PO 4 - .

Claim 5

Salts as claimed in claim 1 of formula ##STR8## in which X is Cl - , 1/2(SO 4 -- ), or H 2 PO 4 - .

Claim 6

A process for preparing S-adenosylmethionine (SAM) salts of formula ##STR9## in which X is the acid equivalent of a strong mineral acid of pK less than 2.5 and n is 4, 5 or 6, characterized in that a concentrated aqueous solution of a crude SAM salt is purified by passage through a weak acid ion exchange resin column, the SAM is eluted with a dilute aqueous solution of the required HX acid, the acid quantity necessary to exactly attain the stoichiometric quantity corresponding to the required salt is added to the eluate, the solution is then concentrated to a value between 50 and 100 g/l; and the high purity salt is separated by lyophilisation.

Claim 7

A process for preparing S-adenosylmethionine (SAM) salts of formula ##STR9## in which X is the acid equivalent of a strong mineral acid of pK less than 2.5 and n is 4, 5 or 6, characterized in that a concentrated aqueous solution of a crude SAM salt is purified by passage through a weak acid ion exchange resin column, the SAM is eluted with a dilute aqueous solution of the required HX acid, the acid quantity necessary to exactly attain the stoichiometric quantity corresponding to the required salt is added to the eluate, the solution is then concentrated to a value between 50 and 100 g/l; and the high purity salt is separated by lyophilisation.

Claim 8

A process as claimed in claim 5, wherein the pH of the aqueous SAM solution is adjusted to between 6 and 7.

Claim 9

A process as claimed in claim 5, wherein the weak acid ion exchange resin is Amberlite IRC 50 or Amberlite CG 50.

Claim 10

A process as claimed in claim 5, wherein the HX acid solution used as eluent has a concentration of 0.1N.

Claim 11

A process as claimed in claim 5, wherein any deficiency of HX acid with respect to the stoichiometric quantity is added to the eluate in the form of a commercial concentrated aqueous solution.

Claim 12

A process as claimed in claim 5, wherein if the eluate contains an excess of HX acid with respect to the stoichiometric quantity, this excess is eliminated by a strong basic ion exchange resin.

Claim 13

A process as claimed in claim 5, wherein the eluate is concentrated to a value of between 50 and 100 g/l of SAM.

Claim 14

A process as claimed in claim 5, wherein lyophilisation is carried out in the presence of an inert substance, preferably mannitol or powdered silicic acid.

Claim 15

Therapeutic compositions for treating hyperlipemia, cholesterolemia or controlling glucide metabolism comprising an anti-hyperlipemially, anti-cholesterolemially or glucide metabolism controlling effective amount of a therapeutic salt of formula ##STR10## in which X is the acid equivalent of a strong mineral acid of pK less than 2.5 and n is 4, 5 or 6, in mixture with therapeutically acceptable excipients and diluents.

Claim 16

Therapeutic compositions for treating hyperlipemia, cholesterolemia or controlling glucide metabolism comprising an anti-hyperlipemially, anti-cholesterolemially or glucide metabolism controlling effective amount of a therapeutic salt of formula ##STR10## in which X is the acid equivalent of a strong mineral acid of pK less than 2.5 and n is 4, 5 or 6, in mixture with therapeutically acceptable excipients and diluents.